Azenta Reports Deepened Q2 Loss on $149M Goodwill Impairment; Key Divestiture Fails to Close

summarizeSummary

Azenta reported a significantly wider Q2 net loss of $160.8 million due to a $149.1 million goodwill impairment. The planned $63.0 million sale of its B Medical Systems business failed to close, and material weaknesses in internal controls persist.

check_boxKey Events

• Significant Net Loss and Goodwill Impairment

  Azenta reported a Q2 FY2026 net loss of $160.8 million, a substantial increase from $47.7 million in Q2 FY2025. This was primarily due to a $149.1 million non-cash goodwill impairment charge in its Multiomics and Sample Management Solutions segments.

• Failed Divestiture of B Medical Systems

  The planned sale of the B Medical Systems business for $63.0 million did not close by March 31, 2026, as the buyer failed to secure financing. Azenta may retain a $5.0 million break-up fee, but the business remains with the company.

• Persistent Material Weaknesses in Internal Controls

  The company's disclosure controls and procedures were not effective as of March 31, 2026, with material weaknesses in cash flow statement review, account reconciliations, and expense classification remaining outstanding.

• Modest Revenue Growth

  Total revenue increased by 1% to $144.8 million for Q2 FY2026, driven by growth in Sample Storage, Product Services, and Next Generation Sequencing, but offset by declines in Core Products and Sanger Sequencing.

auto_awesomeAnalysis

Azenta, Inc. has filed its Q2 FY2026 10-Q, providing full details following the preliminary announcement of results on May 5, 2026. The company reported a significantly widened net loss of $160.8 million for the quarter, compared to a $47.7 million net loss in the prior year, primarily driven by a substantial $149.1 million non-cash goodwill impairment charge across its Multiomics and Sample Management Solutions segments. This impairment reflects a reassessment of fair values due to declining stock price and revised forecasts, indicating significant challenges in these business units.

Adding to the negative news, the planned $63.0 million sale of the B Medical Systems business did not close by the March 31, 2026, deadline because the buyer, Thelema S.A R.L., failed to secure financing. Azenta may now terminate the agreement and retain a $5.0 million break-up fee, but the failure to divest a non-core, loss-making business is a major setback, potentially requiring the company to continue operating it and impacting future financial performance.

Furthermore, Azenta disclosed that material weaknesses in internal controls over financial reporting, previously identified, remain outstanding as of March 31, 2026. While remediation efforts are underway, they have not yet been deemed effective. On a positive note, the company completed the acquisition of UK Biocentre Limited for $27.5 million, expanding its Sample Repository Services in Europe, but this strategic gain is overshadowed by the significant financial losses and operational challenges.